Reuters logo
BRIEF-Seres Therapeutics initiates ser-109 phase 3 study in patients with multiply recurrent c. difficile infection
June 12, 2017 / 11:19 AM / 6 months ago

BRIEF-Seres Therapeutics initiates ser-109 phase 3 study in patients with multiply recurrent c. difficile infection

June 12 (Reuters) - Seres Therapeutics Inc

* Seres Therapeutics initiates ser-109 phase 3 study in patients with multiply recurrent c. Difficile infection

* Seres Therapeutics Inc - based on recent fda interactions, new ser-109 clinical study is to be designated a phase 3 trial

* Seres Therapeutics Inc - phase 3 trial initiation triggers a $20 million milestone payment from nestlé health science

* Seres Therapeutics - plans to accelerate interactions with european regulatory agencies in coming months for ser-109 product approval across europe

* Seres Therapeutics Inc - company expects that single pivotal study may support ser-109 registration and approval Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below